Nordic Issuing

Ongoing case

Fluicell AB

Back to all cases

Fluicell AB

10 Oct - 24 Oct 2022Rights issue

Founded in 2012 as a spin-off from Chalmers University of Technology in Sweden, Fluicell is a public biotech company specializing in high resolution bioprinting and single-cell biology. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.

Fluicell’s ambition is to empower researchers to push the bounds of science for the benefit of human health. We strive to provide state-of-the-art microfluidic platforms and research solutions across bioprinting and single-cell biology. Under the Lab-on-a-tip® umbrella, we have gathered all our instruments, accessories and consumables that will help you create an efficient laboratory workflow and to accelerate progress towards your next discovery.

Read more on the company's website

The offer in summary

Record date: 5 October 2022

Subscription period: 10 October - 24 October 2022

Subscription rights: Anyone who is a shareholder in the Company on the record date of October 5, 2022 has preferential rights to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit right. Six (6) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of five (5) newly issued shares and two (2) free-of-charge warrants of series TO 4.

Subscription price: SEK 12.50 per unit

The offer: Maximum of 2 443 493 units which corresponds to ca MSEK 30.5.

Trading with unit rights: 10 October - 19 October 2022

Marketplace: First North Growth Market

Financial advisor: Sedermera Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.